Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Matt D. Galsky, MD, on Predicting Which Patients With Bladder Cancer Given Neoadjuvant Therapy May Avoid Cystectomy

Posted: Tuesday, June 22, 2021

Matt D. Galsky, MD, of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, discusses study findings on how nivolumab can be integrated with chemotherapy in a neoadjuvant regimen for patients with muscle-invasive bladder cancer and how their response may help clinicians select those who can be spared cystectomy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.